| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9326744 | Gynecologic Oncology | 2005 | 8 Pages |
Abstract
RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited. Although NAC and CTRT are reasonable treatment strategies, policymakers must be willing to spend approximately $500,000 per additional survivor (NAC) or $2.2 M per additional survivor (CTRT).
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Rodney P. Rocconi, Jacob M. Estes, Charles A. III, Larry C. Kilgore, Warner K. Huh, J. Michael Jr.,